Disease · HP_0003546
Exercise intolerance
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Exercise intolerance. Diseases, record HP_0003546. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003546
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Exercise intolerance
- Open Targets ID
- HP_0003546
- Other names
- Decreased ability to exercise, Inability to exercise, Low exercise endurance, Poor exercise tolerance
- Highest stage of its drugs
- Phase 3, for 1 of its 11 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NABIXIMOLS | CHEMBL3833333 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| POTASSIUM NITRATE | CHEMBL1644029 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TREPROSTINIL | CHEMBL1237119 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRIHEPTANOIN | CHEMBL4297585 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SODIUM NITRITE | CHEMBL93268 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1/2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1/2 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1/2 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Phase 2 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| PTGIR | Prostacyclin receptor | 1 | Prostanoid IP receptor agonist | Phase 2 | https://conductscience.org/library/genes/5739 | Drugs and targets |
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02840799 | Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF) | Phase 2 | 84 | 2023-12-18 | Heart Failure | POTASSIUM NITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT02057458 | Blood Flow and Vascular Function in Cystic Fibrosis | Phase 2 | 19 | 2020-04-24 | Cystic Fibrosis | SILDENAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT02178566 | Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso | Phase 2 | 1 | 2022-04-12 | Chronic Obstructive Pulmonary Disease (COPD) | TREPROSTINIL | Its record names the disease | ClinicalTrials.gov |
| NCT06631287 | Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID | Phase 3 | 550 | Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19 | BARICITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03679312 | The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD | Phase 1/2 | 140 | Dyspnea | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04231760 | The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD | Phase 1/2 | 80 | Chronic Obstructive Pulmonary Disease | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05052229 | Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). | Early phase 1 | 40 | Idiopathic Pulmonary Fibrosis | AIR, MEDICAL, NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03060993 | CAN BREATHE in COPD Trial | Phase 2 | 16 | Chronic Obstructive Pulmonary Disease (COPD), Breathlessness, Exercise Intolerance | CANNABIDIOL, DRONABINOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00105222 | Effect of Nitrite on Exercise Physiology and Metabolism | Phase 1 | 15 | Healthy, Healthy Volunteer, HV | SODIUM NITRITE | Its record names the disease | ClinicalTrials.gov | |
| NCT02919631 | Triheptanoin in Mc Ardle | Phase 2 | 12 | Glycogen Storage Disease Type V | TRIHEPTANOIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0003546
GET https://conductscience.org/api/diseases/v1/HP_0003546/drugs